Synergy Pharmaceuticals

Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease. Plecanatide is the Company's uroguanylin analog being evaluated for use as a once-daily tablet for two functional GI disorders, chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Plecanatide is a 16-amino acid peptide that is structurally identical to uroguanylin with the exception of a single amino acid change. Dolcanatide is also its uroguanylin analog being explored for inflammatory bowel disease (IBD). Dolcanatide is designed to be an analog of uroguanylin with resistance to standard digestive breakdown by proteases in the intestine.
New York, US
Size (employees)
116 (est)
Synergy Pharmaceuticals is headquartered in New York, US

Synergy Pharmaceuticals Office Locations

Synergy Pharmaceuticals has an office in New York
New York, US (HQ)
420 Lexington Ave

Synergy Pharmaceuticals Metrics

Synergy Pharmaceuticals Financial Metrics

Synergy Pharmaceuticals's revenue was reported to be $0 in 2016

Net income (Y, 2016)

($198.6 m)

EBIT (Y, 2016)

($42.4 m)

Market capitalization (22-May-2017)

$884.1 m

Closing share price (22-May-2017)


Cash (31-Dec-2016)

$82.4 m
Synergy Pharmaceuticals's current market capitalization is $884.1 m.
FY, 2013FY, 2014FY, 2015Y, 2016



($176.8 m)($94.3 m)($99.8 m)($42.4 m)

Net Income

($171.2 m)($95.7 m)($117.5 m)($198.6 m)
FY, 2013FY, 2014FY, 2015FY, 2016


$18.1 m$146.5 m$61.7 m$82.4 m

Accounts Receivable


$3.7 m$3.8 m$3.3 m$5.6 m

Current Assets

$71.9 m$200.2 m$115.1 m$88.9 m


$589 k$642 k$531 k$593 k

Total Assets

$72.6 m$213.3 m$115.9 m$89.9 m

Accounts Payable

$13.5 m$13.9 m$13.3 m$15.6 m

Current Liabilities

$15.7 m$18.3 m$19.6 m$29.4 m

Additional Paid-in Capital

$226.5 m$261.7 m$329.2 m$620.5 m

Retained Earnings

($266.9 m)($384.4 m)($583 m)

Total Equity

$55.3 m($55.2 m)

Financial Leverage

1.3 x-2.1 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($62.1 m)($95.7 m)($117.5 m)($198.6 m)

Depreciation and Amortization

$56 k$120 k$163 k$233 k

Accounts Receivable


($2.2 m)($124 k)$531 k($5.6 m)

Accounts Payable

$7.1 m$316 k$1.9 m$11.5 m

Cash From Operating Activities

($52.6 m)($89.1 m)($101 m)($129.8 m)

Purchases of PP&E

($615 k)($173 k)($50 k)($297 k)

Cash From Investing Activities

($250 k)$49.8 m

Cash From Financing Activities

$89.2 m$217.1 m$16.4 m$100.7 m

Income Taxes Paid

$81 k$55 k$258 k$45 k

Synergy Pharmaceuticals Market Value History

Synergy Pharmaceuticals Online Presence

Synergy Pharmaceuticals News

Synergy Pharmaceuticals Company Life

You may also be interested in